NCT03845270 - Her2-positive Lung Cancer Treated With Dedicated Drug | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

February 1, 2021

Study Completion Date

December 18, 2023

Conditions

Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIHER2 Gene Mutation

Interventions

DRUG

pertuzumab + trastuzumab + docetaxel

Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²

Trial Locations (18)

14000

Caen - CHU Côte de Nacre, Caen

34295

Montpellier - CHRU, Montpellier

35033

Rennes - CHU, Rennes

72000

Centre Hospitalier - Pneumologie, Le Mans

75020

AP-HP Hopital Tenon - Pneumologie, Paris

Unknown

CHU Besançon, Besançon

CHU de Bordeaux, Bordeaux

Clermont-Ferrand - CHU, Clermont-Ferrand

CHI Créteil, Créteil

CHRU Grenoble, Grenoble

Lyon - URCOT, Lyon

Hôpital Nord APHM, Marseille

CHU de Nantes, Nantes

Nice CLCC, Nice

AP-HP Hôpital Bichat, Paris

CHU Strasbourg, Strasbourg

CHU Toulouse, Toulouse

Gustave Roussy, Villejuif

All Listed Sponsors

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER